ROIV · Roivant Sciences Ltd.
$36.05
-1.21% last session
End-of-day data · close of 2026-10-26
Market cap
$26B
Enterprise value
$23B
Trailing P/E
—
Forward P/E
-21.2
Dividend yield
0.0%
Beta
1.10
Avg volume
7M
Employees
1K
Daily Change %
-1.21%
5 Days Change
11.69%
10 Days Change
12.29%
30 Days Change
1.71%
60 Days Change
3.00%
Month to Day Change
5.49%
Year to Day Change
72.58%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ROIV
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-12
Latest call per bank · past 12 months
Jefferies
Buy$52.00
+42.5% vs priceCitigroup
Buy$46.00
+26.1% vs priceGoldman Sachs
Buy$33.00
-9.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Wolfe Research | Downgrade | Outperform → Peer Perform | $0.00 |
| 2026-09-17 | Stifel | Initiates | Buy | $0.00 → $51.00 |
| 2026-09-09 | TD Cowen | Maintains | Buy | $50.00 → $55.00 |
| 2026-09-09 | Guggenheim | Maintains | Buy | $42.00 → $46.00 |
| 2026-09-08 | HC Wainwright & Co. | Maintains | Buy | $41.00 → $47.00 |
| 2026-09-08 | Jefferies | Maintains | Buy | $42.00 → $52.00 |
| 2026-08-28 | HC Wainwright & Co. | Reiterates | Buy | $41.00 |
| 2026-08-10 | Citigroup | Maintains | Buy | $42.00 → $46.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 51 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 1.6% below the 50-day MA ($36.64).
- bullish: Price vs 200-day MA: Trading 15.5% above the 200-day MA ($31.22).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.30) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($18.22) and high ($41.81).
ROIV Price Chart
Loading chart for ROIV…
Fundamentals
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.